Literatur
- 1 Brandt T, Dichgans J, Diener H C. Therapie und Verlauf neurologischer Erkrankungen.
4. Aufl. Kohlhammer: Stuttgart 2003
- 2
Diener H C.
Leitlinien für Diagnostik und Therapie in der Neurologie.
Thieme: Stuttgart, 2. Aufl.,.
2003;
- 3
Diener H C, Bogousslavsky J, Brass L M. et al .
Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke
or transient ischemic attack in high-risk patients (MATCH): randomised, double-blind,
placebo-controlled trial.
Lancet.
2004;
364
331-337
- 4
Halliday A, Mansfield A, Marro J. et al .
Prevention of disabling and fatal strokes by successful carotid endarterectomy in
patients without recent neurological symptoms: randomised controlled trial.
Lancet.
2004;
363
1491-502
- 5
Yadav J S, Wholey M H, Kuntz R E. et al .
Protected carotid-artery stenting versus endarterectomy in high-risk patients.
N Engl J Med.
2004;
351
1493-1501
- 6
Filippi M, Rovaris M, Inglese M. et al .
Interferon beta-1a for brain tissue loss in patients at presentation with syndromes
suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial.
Lancet.
2004;
364
1489-1496
- 7
Filippi M, Bozzali M, Rovaris M. et al .
Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis.
Brain.
2003;
126
433-337
- 8
Rice G PA, Hartung H P, Calabresi P A.
Anti-alpha 4 integrin therapy for multiple sclerosis: Mechanisms and rationale.
Neurology.
2005;
64
1336-1342
- 9
Singer E.
Tysabri withdrawal calls entire class into question.
Nat Med.
2005;
11
359
- 10
Hartung H P, Gonsette R, Konig N. et al .
Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind,
randomised, multicentre trial.
Lancet.
2002;
360
2018-2025
- 11
Zingler V, Strupp M, Jahn K, Groß A, Hohlfeld R, Brandt T.
The effect of a combined mitoxantrone and methylprednisolone therapy in primary compared
to secondary progressive multiple sclerosis.
Nervenarzt.
, (im Druck)
- 12
Russmann H, Ghika J, Villemure J G, Robert B, Bogousslavsky J, Burkhard P R, Vingerhoets F J.
Subthalamic nucleus deep brain stimulation in Parkinson disease patients over age
70 years.
Neurology.
2004;
63
1952-1954
- 13
Freed C R, Greene P E, Breeze R E. et al .
Transplantation of embryonic dopamine neurons for severe Parkinson’s disease.
N Engl J Med.
2001;
344
710-719
- 14
Bittar R G, Yianni J, Wang S. et al .
Deep brain stimulation for generalised dystonia and spasmodic torticollis.
J Clin Neurosci.
2005;
12
12-16
- 15
Tellez-Zenteno J F, Dhar R, Wiebe S.
Long-term seizure outcomes following epilepsy surgery: a systematic review and meta-analysis.
Brain.
2005;
128
1188-1198
- 16 Brandt T, Dieterich M, Strupp M. Vertigo - Leitsymptom Schwindel. Steinkopff, Darmstadt
2004
- 17
Strupp M, Zingler V, Arbusow V. et al .
Methylprednisolone, valacyclovir, or the combination for vestibular neuritis.
N Engl J Med.
2004;
351
354-361
- 18
Strupp M, Schüler O, Krafczyk S. et al .
Treatment of downbeat nystagmus with 3,4-diaminopyridine: a placebo-controlled study.
Neurology.
2003;
61
165-170
- 19
Strupp M, Kalla R, Dichgans M. et al .
Treatment of episodic ataxia type 2 with the potassium channel blocker 4-aminopyridine.
Neurology.
2004;
62
1623-1625
Prof. Dr. Michael Strupp
Neurologische Klinik, LMU München, Universitätsklinikum Großhadern
Marchioninistraße 15
81366 München
Phone: ++49/89/70953678
Fax: ++49/89/70956673
Email: Michael.Strupp@med.uni-muenchen.de
